Voydeya™ (danicopan)
for Paroxysmal Nocturnal Hemoglobinuria
Voydeya (danicopan) is an oral complement factor D inhibitor used to treat extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is an add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) for patients with insufficient response. Voydeya works by inhibiting complement Factor D, preventing EVH, and reducing red blood cell destruction outside blood vessels, while helping maintain control over intravascular hemolysis.
